ThromboGenics two-year OASIS study confirms Jetrea efficacy and safety

Belgian biotech firm ThromboGenics (Euronext Brussels: THR), today announced positive results from its two-year OASIS Phase IIIb study with Jetrea (ocriplasmin) have been published in the renowned AAO Journal Ophthalmology.

Ophthalmology reviewed the OASIS Phase IIIb randomized, sham controlled, double masked study that followed up patients for 24 months post injection. The study was designed to provide long term controlled efficacy and safety data for Jetrea in patients being treated for symptomatic vitreomacular adhesion (sVMA). The study included 24 months follow up data, the longest period patients have been studied post treatment with this novel medicine.

In its overall conclusion, Ophthalmology confirms “the OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous Phase III trials with no additional safety signals identified.”